Good news for pet owners pubmed.ncbi.nlm.nih.gov/36706080/ Joey Mattingly

Long shot but are there any health economist out there would would review a journal paper for me? My last PhD by publication paper has been stuck in one journal for 5 months with no reviewers, I think it is now down to me to find one!

Antimicrobial resistance or #AMR, as known in short, is a global health crisis. Find out how we're applying a new 'Netflix' style payment model to boost the antimicrobial pipeline, which has already assessed 2 new antimicrobial drugs⬇️ link.springer.com/article/10.100…

BCN Health publishes a study reviewing economic evaluations and burden of disease studies of endometriosis #health #review #economic #evaluation #burden #disease #endometriosis #costs #indirect #productivity #losses bit.ly/3EBmAZT

At IPHA's conference. The Minister just mentioned Ireland's €45,000/QALY threshold and that there is an existing pathway for orphan drugs to exceed it. Interesting confirmation of the threshold and that it doesn't always apply.

In preparation for my new class Harris Policy, I asked ChatGPT: “How to conduct cost-effectiveness analysis (CEA)?” ChatGPT provides a very solid high-level summary, and I don’t think I can do a better job. Thoughts? Peter Neumann Anirban Basu Ankur Pandya Davene R. Wright, PhD

Congratulations Dina Abushanab on this massive work on projecting the health and economic burden of CVD among people with type 2 diabetes @claremarquina Jedidiah Morton Chris Carswell link.springer.com/article/10.100…

Terrible grammar is a key sign!

Thread update on the QUOKKA project led by the brilliant nance devlin - huge output from this multi-university project on measuring and valuing child QoL

Happy to see this work published with nance devlin tianxinpan Mark Sculpher Mark Jit Donna Rowen Ben van Hout and Richard Norman! We highlight fundamental questions around the valuation of child health for use in economic evaluation that need to be resolved! #eq5dY @euroqol

1/3 "Using Age-Specific Values for Pediatric HRQoL in CEA: Is There a Problem to Be Solved? If So, How?" available here👉 tinyurl.com/45xn56sk Really pleased this paper is out - hope it serves to progress the debate! Elly Stolk Mark Sculpher Richard Norman QUOKKA Research Program

Including carer outcomes in economic evaluation is important & can reveal unrecognised challenges in HTA decisions. One of these is where patient & carer QALYs point in different directions - work led by @davidjohnmott and colleagues Office of Health Economics Health Economics Unit, Birmingham link.springer.com/article/10.100…

My 'Framework for the Fair Pricing of Medicines' has just been published as a Leading Article by Pharmacoeconomics. This framework proposes a number of advancements to existing approaches for specifying a 'cost-effectiveness threshold' for new medicines. link.springer.com/article/10.100…

Second, this solo editorial in Pharmacoeconomics, called "Making Models Fit for Purpose: the Importance of Ensuring Stakeholder Involvement". Also available free right here! rdcu.be/dwnP1

If you read, write or review papers on discrete choice experiments in health & healthcare, you may have noticed that reporting is a bit patchy. We hope that this new reporting checklist will help with that! Pls try it out and let us know how you go. doi.org/10.1007/s40273…

A much needed reporting checklist for discrete choice experiments link.springer.com/article/10.100…

Seems to me the QALY is so entrenched in many countries it would take a huge effort to move away from it

PharmacoEconomics has a Call For Papers for a themed issue on individual level models link.springer.com/collections/jf…

I’ll be attending the Australian Health Economics Society conference this week in Sydney, so feel free to chat to me there about this job if you’ve got questions linkedin.com/jobs/view/4017…

linkedin.com/posts/christop…